Physician profile
Casey Feeney
NPI 1861994683
$6,489.13
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,635 · 2022: $873 · 2023: $1,469 · 2024: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,981.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,115.09 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $803.94 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $778.93 | 2021-2024 | |
| Insulet Corporation | $461.08 | 2021-2024 | Omnipod |
| Lilly USA, LLC | $429.93 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $371.49 | 2022-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $274.26 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $232.20 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.48 | 2022-2024 | |
| Gilead Sciences, INC. | $184.19 | 2022-2024 | Epclusa |
| Amgen INC. | $160.67 | 2021-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.31 | 2021-2023 | Jardiance |
| Dexcom, INC. | $143.07 | 2021-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $139.85 | 2021-2024 | Eliquis, Camzyos |
| Abbott Laboratories | $137.79 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $134.70 | 2021-2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $102.24 | 2024 | Voquezna |
| Exact Sciences Corporation | $101.71 | 2023-2024 | Cologuard Collection Kit |
| Viiv Healthcare Company | $71.12 | 2022-2024 | Dovato |
| Janssen Pharmaceuticals, INC | $66.90 | 2021 | |
| Scilex Pharmaceuticals INC. | $56.20 | 2021 | |
| Grifols USA, LLC | $50.92 | 2021 | |
| Advanced Oxygen Therapy INC. | $44.98 | 2022-2023 | Topical Oxygen Chamber For Extremities |
| Indivior INC. | $41.31 | 2023 | Sublocade |
| Novartis Pharmaceuticals Corporation | $39.51 | 2023 | Leqvio, Entresto |
| Almatica Pharma LLC | $35.39 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.27 | 2022 | |
| Aurinia Pharma U.S., INC. | $23.66 | 2023 | Lupkynis |
| Astellas Pharma US INC | $22.79 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $22.35 | 2022 | |
| Hologic Sales and Service, LLC | $20.92 | 2024 | Aptima |
| Xeris Pharmaceuticals, INC. | $20.71 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.16 | 2023 | |
| Eisai INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Feeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.